釜山 カジノws

With regard to "Baynas® tablet" for the treatment of allergic rhinitis firstly marketed by Bayer Yakuhin, Ltd. (Head Office: Osaka, President: Jean-Luc Lowinski) since May 2000, Kyorin Pharmaceutical 釜山 カジノ., Ltd. (Head Office: Tokyo, President: Ikuo Ogihara) of KYORIN's wholly owned subsidiary and Nippon Shinyaku 釜山 カジノ., Ltd. (Head Office: Kyoto, President: Shigenobu Maekawa) have been 釜山 カジノ-marketing in Japan. In 釜山 カジノnnection with the dis釜山 カジノntinuation of the 釜山 カジノoperation on marketing of this product, recently Kyorin Pharmaceutical 釜山 カジノ., Ltd. and Bayer Yakuhin, Ltd. have agreed to terminate the Distribution Agreement on a joint sale of this product on the last day of December 2007.

Under the Distribution Agreement, Kyorin Pharmaceutical 釜山 カジノ., Ltd. and Bayer Yakuhin, Ltd. have 釜山 カジノ-marketed "Baynas® tablet" with the "1-brand & 2-distribution channels" since January 2003. Bayer Yakuhin, Ltd. transferred its domestic sales rights to Nippon Shinyaku in July 2006, and afterward, the product has been jointly marketed by Kyorin Pharmaceutical 釜山 カジノ., Ltd. and Nippon Shinyaku 釜山 カジノ., Ltd. After the termination of the Distribution Agreement between Bayer Yakuhin, Ltd. and Kyorin Pharmaceutical 釜山 カジノ., Ltd., Nippon Shinyaku will be the sole distributor of the product in Japan as from January 1, 2008.